neovascular (wet) AMD
Conditions
Interventions
In the study eye, subjects will receive 2 mg (0.05 mL) intravitreal injection of AVT06 or Eylea every 4 weeks for 3 consecutive monthly visits (Day 1, Week 4, and Week 8) followed by intravitreal inje
Sponsors
Koelbl Stephanie
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Subject must be >= 50 years of age, at the time of signing the informed consent. - Subjects must be diagnosed with neovascular (wet) AMD in the study eye. - Subjects must have active, treatment naive, subfoveal CNV lesions secondary to neovascular (wet) AMD. - Willingness and ability to undertake all scheduled visits and assessments.
Exclusion criteria
Exclusion criteria: - Any prior systemic treatment with anti-VEGF therapy - Any condition that, in the Investigator's opinion, can interfere with full participation in the study, including administration of the study treatment and attending required visits; can pose a significant risk to the participant, or interfere with interpretation of study data - Prior treatment with any investigational drugs within 30 days or 5 half-lives (whichever is longer) of the previous investigational treatment before initiation of the study treatment or concomitant enrollment in any other clinical study involving an investigational study treatment - Subjects not suitable for participation, whatever the reason, as judged by the Investigator, including medical or psychiatric conditions, or participants potentially at risk of noncompliance to study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to Week 8 in BCVA as measured by ETDRS letter score. | — |
Countries
Argentina, Brazil, Bulgaria, Czech Republic, Georgia, Hungary, India, Japan, Latvia, Poland, Russia, Slovakia, Ukraine
Contacts
Public ContactjRCT Inquiry Contact IQVIA Services Japan G.K.
IQVIA Services Japan G.K.
Outcome results
None listed